| 注册
首页|期刊导航|中国临床药理学杂志|利福喷丁与利福平治疗HBsAg阳性肺结核患者的临床研究

利福喷丁与利福平治疗HBsAg阳性肺结核患者的临床研究

宗玲青 高胜利 凌丽华 卫峰 刘艳 叶扬

中国临床药理学杂志2023,Vol.39Issue(23):3365-3369,5.
中国临床药理学杂志2023,Vol.39Issue(23):3365-3369,5.DOI:10.13699/j.cnki.1001-6821.2023.23.005

利福喷丁与利福平治疗HBsAg阳性肺结核患者的临床研究

Clinical trial of rifapentine and rifampin in the treatment of HBsAg positive pulmonary tuberculosis patients

宗玲青 1高胜利 1凌丽华 1卫峰 1刘艳 1叶扬1

作者信息

  • 1. 苏州市第九人民医院感染病科,江苏苏州 215000
  • 折叠

摘要

Abstract

Objective To observe the clinical efficacy of levofloxacin combined with levofloxacin scheme in the treatment of pulmonary tuberculosis patients with positive hepatitis B surface antigen(HBsAg)and its impact on drug-induced liver injury.Methods Pulmonary tuberculosis patients with positive HBsAg were divided into treatment group and control group according to the anti-tuberculosis treatment plan.The treatment group received 2HLZE/4HLE anti-tuberculosis regimen(levofloxacin 0.6 g,twice a week+isoniazid 0.3 g,qd+ethambutol hydrochloride 0.75 g,qd+pyrazinamide 0.5 g,tid)for 6 months,and the control group received 2HRZE/4HRE anti-tuberculosis regimen(levofloxacin 0.6 g,qd+isoniazid 0.3 g,qd+ethambutol hydrochloride 0.75 g,qd+pyrazinamide 0.5 g,tid)for 6 months.The sputum smear conversion rate,liver function indicators[glutamate pyruvate transaminase(GPT),glutamate oxaloacetate transaminase(GOT),serum total bilirubin(TBIL)],clinical efficacy,drug-induced liver injury,as well as the incidence of adverse drug reactions were compared between the two groups.Results A total of 41 patients were enrolled in the treatment group and 39 patients in the control group.After treatment,the clinical total effective rates in the treatment and control groups were 97.56%and 79.49%,which showed statistically significant difference(P<0.05).After 4 months of treatment,the sputum smear conversion rates in the treatment group and the control group were 90.24%and 71.79%,respectively;after 6 months of treatment,the sputum smear conversion rates in the treatment group and the control group were 95.12%and 79.49%,respectively,both showing statistically significant differences(all P<0.05).After 6 months of treatment,the GPT levels in the treatment group and the control group were(87.39±17.26)and(101.49±23.48)U·L-1,the GOT levels were(97.54±19.25)and(119.63±21.57)U·L-1,and the TBIL levels were(31.53±9.35)and(38.27±9.64)μmol·L-1,respectively,all showing statistically significant differences(all P<0.05).The incidence of drug-induced liver injury in the treatment group and the control group was 19.51%and 41.03%respectively,and the time of liver injury occurrence was(12.98±2.26)and(10.23±1.95)days,both showing statistically significant differences(all P<0.05).The total incidences of adverse reactions in the treatment group and the control group was 29.27%and 64.10%respectively,with statistically significant differences(P<0.05).Conclusion Compared with the levofloxacin scheme,the levofloxacin combined with levofloxacin scheme can reduce the incidence and severity of drug-induced liver injury and improve the clinical treatment efficacy in pulmonary tuberculosis patients with positive HBsAg.

关键词

利福喷丁胶囊/利福平胶囊/肺结核/药物性肝损伤

Key words

pulmonary tuberculosis capsule/rifampicin capsule/pulmonary tuberculosis/drug-induced liver injury

分类

医药卫生

引用本文复制引用

宗玲青,高胜利,凌丽华,卫峰,刘艳,叶扬..利福喷丁与利福平治疗HBsAg阳性肺结核患者的临床研究[J].中国临床药理学杂志,2023,39(23):3365-3369,5.

中国临床药理学杂志

OA北大核心CSCDCSTPCD

1001-6821

访问量0
|
下载量0
段落导航相关论文